UNSPSC 51313504: Dimetholizine

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6U9W3DMYT. European Medicines Agency schedules Dimetholizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07174MIG. Dimetholizine generally arises in the molecular formula C15H24N2O2.

UNSPSC 51313504 Dimetholizine is a Commodity code, but state and local procurement under this code shows minimal activity aligned with the nominal substance. The recent opportunities tagged to this code actually center on naloxone procurement, pharmaceutical benefit program restructuring, and generic multi-source pharmaceutical distribution—none of which involve dimetholizine directly. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple states and localities. The mismatch between the code's narrow pharmaceutical substance designation and the broader pharmaceutical-procurement activity shows in the opportunities: Seminole County, Florida (county health department) is soliciting naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission is gathering market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, is establishing statewide and multi-state contracts for generic pharmaceuticals and OTC products across participating jurisdictions including Oregon.

Geographic activity concentrates in Florida, Texas, and Minnesota with multi-state participation through MMCAP. The Seminole County IFB (IFB60459723LAS) due July 26, 2026 (per the posted date metadata, though the summary contains an inconsistent 2023 date) seeks 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries; vendors must include shipping costs and meet E-Verify and drug-free workplace compliance. The Texas HHS Commission's RFI (HHS0017013) posted April 3, 2026 explores vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels, functioning as preliminary market intelligence rather than a binding solicitation. MMCAP's RFP (S1070000015802) due March 26, 2026 establishes multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awarded vendors effective July 1, 2026; evaluation weighs price competitiveness (75 percent) and administrative requirements (25 percent combined), and vendors must maintain $5 million commercial general liability and $2 million network security and professional liability coverage. The code shows limited substantive activity directly relevant to dimetholizine procurement.